酒石酸溴莫尼定0．15％滴眼液治疗开角型青光眼及高眼压症的临床研究

Clinical study of 0. 15% brimonidine tartrate eye drops for the treatment of primary open angle glaucoma and ocular hypertension

目的评价0．15％酒石酸溴莫尼定（阿法舒）滴眼液降眼压的有效性和安全性。方法初诊原发性开角型青光眼或高眼压症46例（86只眼）单用或联合应用阿法舒滴眼液，3次／d，每次1滴。将连续滴药后2、4、8、12周的眼压与基线眼压进行比较研究，同时观察全身及局部副作用。结果使用阿法舒滴眼液后眼压均明显下降。由（22．89±3．91）mmHg（1mmHg=0．133kPa）分别下降为滴药后2、4、8、12周的（19．43±2．84）mmHg、（19．43±3．44）mmHg、（18．98±3．17）mmHg和（18．87±2．83）mmHg，用药后与治疗前比较差异均有统计学意义（P〈0．01）。初诊单纯使用阿法舒者，及换用或加用阿法舒者用药后与治疗前比较差异均有统计学意义（P〈0．01）。不良反应均为轻度。结论阿法舒滴眼液能显著降低原发性开角型青光眼及高眼压症患者的眼压，有效并且安全。

Objective To investigate the efficacy and safety of 0. 15% brimonidine tartrate （Alphagan P）eye drops. Methods 86 eyes of 46 cases with primary open angle glaucoma （POAG） or ocular hypertension were dosed with Alphagan P eye drops alone or as an adjunctive therapy as one drop a time, thrice daily. The intraocular pressure （IOP） at 2, 4, 8 and 12 weeks after sustained instilling were compared with the baseline. On the other hand, systematic and local adverse effects were also observed. Results Alphagan P eye drops reduced IOP significantly. The mean IOP decreased from the baseline （22.89 ±3.91）mmHg（1 mmHg =0. 133 kPa） to（19.43±2.84）, （19.43 ±3.44）, （18.98 ±3.17）and （ 18.87 ± 2.83） mmHg at 2, 4, 8 and 12 weeks after sustained instilling respectively. There were statistical differences between baseline and the IOP at four time points （ P 〈 0.01 ）. No matter dropped Alphagan P alone or taken it as an adjunetive therapy or switched to Alphagan P during trentment, there were statistical differences between baseline and the IOP at four time points after sustained instilling （P 〈 0.01 ）. The major adverse effects didn＇ t affect continuous medication. Conclusion Alphagan P eye drops can reduce IOP significantly in the patients with POAG or ocular hypertension. It is safe and effective.